×
About 24,478 results

ALLMedicine™ Hypoglycemia Center

Research & Reviews  11,097 results

Long-term incidence of hypoglycemia-related events after bariatric surgery or usual car...
https://doi.org/10.1111/dom.14420
Diabetes, Obesity & Metabolism; Sjöholm K, Jacobson P et. al.

May 7th, 2021 - Hypoglycemia is a potentially serious side effect of bariatric surgery but long-term outcomes from prospective, controlled trials are lacking. We therefore examined the incidence of hypoglycemia-related events over up to 31 years in patients treat...

Ten-years outcomes of islet transplantation in patients with type 1 diabetes: data from...
https://doi.org/10.1111/ajt.16637
American Journal of Transplantation : Official Journal Of... Lablanche S, Borot S et. al.

May 7th, 2021 - To describe the 10-year outcomes of islet transplantation within the Swiss-French GRAGIL Network, in patients with type 1 diabetes experiencing high glucose variability associated with severe hypoglycemia and/or with functional kidney graft. We co...

Transient hypoglycemia as a rare cause of recurring transient loss of consciousness: a ...
https://doi.org/10.1186/s13256-021-02844-z 10.1093/eurheartj/ehy071 10.1111/j.1365-2265.2006.02629.x 10.1093/eurheartj/ehy037 10.1056/NEJMoa012407 10.1016/S1525-5050(03)00104-5 10.1093/eurheartj/ehy339 10.1093/ajcn/85.5.1185 10.2337/diacare.18.11.1415 10.4236/ijcm.2011.22023 10.1111/ijcp.12426 10.1111/j.1749-6632.1968.tb27760.x
Journal of Medical Case Reports; Wester M, Bergmann T et. al.

May 6th, 2021 - Syncopes and transient loss of consciousness affect a large number of patients. Determining the underlying mechanism of a syncope is key to effectively treating and preventing future events. However, given the broad differential diagnosis of trans...

Glucose-lowering action through targeting islet dysfunction in type 2 diabetes - focus ...
https://doi.org/10.1111/jdi.13564
Journal of Diabetes Investigation; Ahrén B

May 5th, 2021 - Dipeptidyl peptidase-4 (DPP-4) inhibition is a glucose-lowering medication for type 2 diabetes. It works through stimulation of insulin secretion and inhibition of glucagon secretion in a glucose-dependent manner, resulting in lowered fasting and ...

New genetic and clinical evidence associated with fetal Beckwith-Wiedemann syndrome.
https://doi.org/10.1002/pd.5956
Prenatal Diagnosis; Traisrisilp K, Chankhunaphas W et. al.

May 3rd, 2021 - Early detection of Beckwith-Wiedemann syndrome (BWS) is very important since it is very useful regarding counseling of parents concerning the risk of developing embryonic tumors, selection of the mode of delivery due to potential adrenal cysts tha...

see more →

Guidelines  49 results

Management and Appropriate Use of Diazoxide in Infants and Children with Hyperinsulinism.
https://doi.org/10.1210/clinem/dgaa543
The Journal of Clinical Endocrinology and Metabolism; Brar PC, Heksch R et. al.

Aug 18th, 2020 - The diagnosis of hypoglycemia and the use of diazoxide have risen in the last decade. Diazoxide is the only Food and Drug Agency-approved pharmacologic treatment for neonatal hypoglycemia caused by hyperinsulinism (HI). Recent publications have hi...

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
https://www.nejm.org/doi/full/10.1056/NEJMoa1911303
The New England Journal of Medicine; McMurray,J.,et al

Sep 18th, 2019 - BACKGROUND In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the eff...

Xeris Pharmaceuticals Receives U.S. Fda Approval For Gvoke™ (Glucagon), The First Ready-to-use Stable Liquid Glucagon For Severe Hypoglycemia
https://xerispharma.gcs-web.com/news-releases/news-release-details/xeris-pharmaceuticals-receives-us-fda-approval-gvoketm-glucagon

Sep 9th, 2019 - Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced today that it has received reg...

BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA
https://investor.lilly.com/news-releases/news-release-details/baqsimitm-glucagon-nasal-powder-3-mg-first-and-only-nasally

Jul 23rd, 2019 - The U.S. Food and Drug Administration (FDA) has approved BAQSIMI™ (glucagon) nasal powder 3 mg for the treatment of severe hypoglycemia in people with diabetes ages four years and above, Eli Lilly and Company (NYSE: LLY) announced today. BAQSIMI i...

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors
http://care.diabetesjournals.org/content/42/6/1147
Diabetes Care; Danne,T.,et al

May 31st, 2019 - Sodium–glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia...

see more →

Drugs  93 results see all →

Clinicaltrials.gov  11,979 results

Long-term incidence of hypoglycemia-related events after bariatric surgery or usual car...
https://doi.org/10.1111/dom.14420
Diabetes, Obesity & Metabolism; Sjöholm K, Jacobson P et. al.

May 7th, 2021 - Hypoglycemia is a potentially serious side effect of bariatric surgery but long-term outcomes from prospective, controlled trials are lacking. We therefore examined the incidence of hypoglycemia-related events over up to 31 years in patients treat...

Ten-years outcomes of islet transplantation in patients with type 1 diabetes: data from...
https://doi.org/10.1111/ajt.16637
American Journal of Transplantation : Official Journal Of... Lablanche S, Borot S et. al.

May 7th, 2021 - To describe the 10-year outcomes of islet transplantation within the Swiss-French GRAGIL Network, in patients with type 1 diabetes experiencing high glucose variability associated with severe hypoglycemia and/or with functional kidney graft. We co...

Transient hypoglycemia as a rare cause of recurring transient loss of consciousness: a ...
https://doi.org/10.1186/s13256-021-02844-z 10.1093/eurheartj/ehy071 10.1111/j.1365-2265.2006.02629.x 10.1093/eurheartj/ehy037 10.1056/NEJMoa012407 10.1016/S1525-5050(03)00104-5 10.1093/eurheartj/ehy339 10.1093/ajcn/85.5.1185 10.2337/diacare.18.11.1415 10.4236/ijcm.2011.22023 10.1111/ijcp.12426 10.1111/j.1749-6632.1968.tb27760.x
Journal of Medical Case Reports; Wester M, Bergmann T et. al.

May 6th, 2021 - Syncopes and transient loss of consciousness affect a large number of patients. Determining the underlying mechanism of a syncope is key to effectively treating and preventing future events. However, given the broad differential diagnosis of trans...

Glucose-lowering action through targeting islet dysfunction in type 2 diabetes - focus ...
https://doi.org/10.1111/jdi.13564
Journal of Diabetes Investigation; Ahrén B

May 5th, 2021 - Dipeptidyl peptidase-4 (DPP-4) inhibition is a glucose-lowering medication for type 2 diabetes. It works through stimulation of insulin secretion and inhibition of glucagon secretion in a glucose-dependent manner, resulting in lowered fasting and ...

In-Hospital Glucose Management Program Gives Dramatic Savings
https://www.medscape.com/viewarticle/950563

May 4th, 2021 - Initiatives targeting hypoglycemia and insulin pen wastage could lead to dramatic cost savings in small community hospitals, new data suggest. The two projects are part of a dedicated inpatient glucose management service led by Mihail ("Misha") Zi...

see more →

News  1,213 results

In-Hospital Glucose Management Program Gives Dramatic Savings
https://www.medscape.com/viewarticle/950563

May 4th, 2021 - Initiatives targeting hypoglycemia and insulin pen wastage could lead to dramatic cost savings in small community hospitals, new data suggest. The two projects are part of a dedicated inpatient glucose management service led by Mihail ("Misha") Zi...

FDA Approves New Ready-to-Inject Glucagon Product
https://www.medscape.com/viewarticle/947962

Mar 22nd, 2021 - The US Food and Drug Administration (FDA) has approved dasiglucagon (Zegalogue 0.6 mg/0.6 mL, Zealand Pharma) autoinjector and prefilled syringe for the treatment of severe hypoglycemia in people with diabetes aged 6 and older. The product has a s...

Pumps and Patches: Technology Benefits Youth With Type 1 Diabetes
https://www.medscape.com/viewarticle/947742

Mar 18th, 2021 - An increase in the use of insulin pumps and continuous glucose monitoring (CGM) around the world is benefiting children with type 1 diabetes, new research finds. An analysis of data for more than 25,000 participants aged 18 years or younger with t...

Less Risk of Severe Hypoglycemia With Long-Acting Insulin Analogs in Elderly
https://www.medscape.com/viewarticle/946662

Mar 1st, 2021 - NEW YORK (Reuters Health) - Long-acting insulin analogs may be a safer option than neutral protamine Hagedorn (NPH, also known as isophane insulin) in elderly patients with type 2 diabetes initiating insulin therapy, according to a large observati...

Continuous Glucose Monitoring Curbs Hyperglycemia, Hypoglycemia in Preemies
https://www.medscape.com/viewarticle/946348

Feb 24th, 2021 - NEW YORK (Reuters Health) - In preterm infants, continuous glucose monitoring (CGM) reduced prolonged or severe hyperglycemia and hypoglycemia in an international randomized controlled trial. Both conditions "are associated with long-term harm," D...

see more →

Patient Education  47 results see all →